Hainan Shuangcheng Pharmaceut - Asset Resilience Ratio
Hainan Shuangcheng Pharmaceut (002693) has an Asset Resilience Ratio of 1.03% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hainan Shuangcheng Pharmaceut strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Hainan Shuangcheng Pharmaceut's Asset Resilience Ratio has changed over time. See 002693 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hainan Shuangcheng Pharmaceut's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Hainan Shuangcheng Pharmaceut worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥8.41 Million | 1.03% |
| Total Liquid Assets | CN¥8.41 Million | 1.03% |
Asset Resilience Insights
- Limited Liquidity: Hainan Shuangcheng Pharmaceut maintains only 1.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Shuangcheng Pharmaceut Industry Peers by Asset Resilience Ratio
Compare Hainan Shuangcheng Pharmaceut's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Hainan Shuangcheng Pharmaceut (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Hainan Shuangcheng Pharmaceut.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | CN¥46.43K ≈ $6.79K |
CN¥825.78 Million ≈ $120.84 Million |
+0.01pp |
| 2024-12-31 | 0.00% | CN¥2.83K ≈ $413.53 |
CN¥783.87 Million ≈ $114.70 Million |
-3.55pp |
| 2023-12-31 | 3.55% | CN¥28.52 Million ≈ $4.17 Million |
CN¥803.25 Million ≈ $117.54 Million |
-11.14pp |
| 2022-12-31 | 14.69% | CN¥133.81 Million ≈ $19.58 Million |
CN¥911.02 Million ≈ $133.31 Million |
+8.20pp |
| 2021-12-31 | 6.48% | CN¥55.40 Million ≈ $8.11 Million |
CN¥854.56 Million ≈ $125.05 Million |
-3.90pp |
| 2020-12-31 | 10.38% | CN¥94.25 Million ≈ $13.79 Million |
CN¥907.68 Million ≈ $132.82 Million |
+4.83pp |
| 2019-12-31 | 5.55% | CN¥52.80 Million ≈ $7.73 Million |
CN¥950.98 Million ≈ $139.16 Million |
-6.94pp |
| 2018-12-31 | 12.50% | CN¥139.98 Million ≈ $20.48 Million |
CN¥1.12 Billion ≈ $163.93 Million |
+1.80pp |
| 2017-12-31 | 10.69% | CN¥147.25 Million ≈ $21.55 Million |
CN¥1.38 Billion ≈ $201.52 Million |
+10.26pp |
| 2016-12-31 | 0.43% | CN¥5.00 Million ≈ $731.66K |
CN¥1.17 Billion ≈ $170.55 Million |
+0.21pp |
| 2015-12-31 | 0.22% | CN¥3.37 Million ≈ $493.14K |
CN¥1.55 Billion ≈ $226.84 Million |
-40.06pp |
| 2014-12-31 | 40.27% | CN¥380.00 Million ≈ $55.61 Million |
CN¥943.54 Million ≈ $138.07 Million |
-- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more